Successful and Safe Reinstitution of Chemotherapy for Pancreatic Cancer after COVID-19

Cancer patients are regarded as highly vulnerable to severe acute respiratory syndrome coronavirus (SARS-CoV)-2. However, little is known regarding how cancer treatments should be restarted for cancer patients after coronavirus disease (COVID)-19. We herein report a pancreatic cancer case in which c...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagai, Kazumasa, Kitamura, Katsuya, Hirai, Yuji, Nutahara, Daisuke, Nakamura, Hironori, Taira, Junichi, Matsue, Yubu, Abe, Masakazu, Kikuchi, Miho, Itoi, Takao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872796/
https://www.ncbi.nlm.nih.gov/pubmed/33229812
http://dx.doi.org/10.2169/internalmedicine.6294-20
Descripción
Sumario:Cancer patients are regarded as highly vulnerable to severe acute respiratory syndrome coronavirus (SARS-CoV)-2. However, little is known regarding how cancer treatments should be restarted for cancer patients after coronavirus disease (COVID)-19. We herein report a pancreatic cancer case in which chemotherapy was able to be reinstituted after COVID-19. The patient was a 67-year-old man diagnosed with pancreatic cancer. On day 7 after first chemotherapy, he was infected with COVID-19. A SARS-CoV-2 test was negative after one month of treatment, and we reinstituted chemotherapy. The patient has received three cycles of chemotherapy without recurrence of COVID-19. It may be feasible to reinstitute chemotherapy for cancer patients after a negative SARS-CoV-2 test.

Ejemplares similares